Navigation Links
CryoCath Presents at Prestigious Heart Rhythm Society Meeting
Date:5/20/2008

http://www.cryocath.com Toronto Stock Exchange Symbol: CYT

MONTREAL, May 20 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, is pleased to report on its participation in Heart Rhythm 2008, the most prominent and comprehensive educational event on heart rhythm disorders. The event was held from May 14 to 17 at the Moscone Convention Center in San Francisco. This year, the meeting attracted a record-breaking 13,600 attendees and provided 250 educational opportunities in multiple formats. The world's leading electrophysiologists presented a broad range of heart rhythm topics.

CryoCath marked its presence at this prestigious gathering with 12 poster presentations and 10 well-attended oral presentations. For the most part, these presentations focused on the Arctic Front(R) cryoballoon system for pulmonary-vein isolation in the treatment of paroxysmal atrial fibrillation. Other presentations dealt with CryoCath's family of focal catheters for the treatment of a range of arrhythmias.

CryoCath's presence at Heart Rhythm 2008 provided the company with an excellent opportunity to further familiarize physicians with the growing body of evidence in favour of the cryoballoon approach in the treatment of AF. This included the consistent, positive results from multiple centres reported at the most recent Annual Meeting of the German Cardiac Society in Mannheim in March 2008.

A continuing area of discussion among electrophysiologists throughout the Heart Rhythm meeting was the possibility of injury and potentially fatal esophageal fistula due to ablation. Specifically, two presentations focused on this problem. As reported by Dr. Hiroshi Nakagawa, an animal study found that heat-based ablations can cause progressive ulceration of the esophagus, leading to esophagitis and fistula. In contrast, further study on the effects to the esophagus with cryoablation found that while cryo can cause ulcerations, they heal quickly. Furthermore, with cryoablation there was no esophagitis and no fistula formation. These findings, regarding the effects of cryo-based ablation on the esophagus, were reinforced by results in a clinical case study with Arctic Front reported by Dr. Vivek Reddy.

About Arctic Front

Arctic Front is a minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal Atrial Fibrillation. This bi-directional, double balloon catheter enables physicians to rapidly isolate all four pulmonary veins for the treatment of AFib. Over 2,600 patients have been treated in over 45 centres across Europe.

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.


'/>"/>
SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. CryoCath announces 2007 fourth quarter and fiscal year end financial results
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
7. CryoCath Provides Update on Patent Infringement Lawsuit
8. CryoCath Announces Fiscal 2008 First Quarter Results
9. CryoCath Technologies notice of annual meeting
10. CryoCath Appoints New Chief Financial Officer
11. CryoCath Introduces Arctic Front in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... ... , ... While it’s often important to take certain medications during the night, ... has identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX ... eliminates the need to turn on a light when taking medication during the night, ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: